Retail Investors Are Hangzhou Biotest Biotech Co.,Ltd.'s (SHSE:688767) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥404m Last Week
Retail Investors Are Hangzhou Biotest Biotech Co.,Ltd.'s (SHSE:688767) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥404m Last Week
Key Insights
关键见解
- The considerable ownership by retail investors in Hangzhou Biotest BiotechLtd indicates that they collectively have a greater say in management and business strategy
- 55% of the business is held by the top 3 shareholders
- Insider ownership in Hangzhou Biotest BiotechLtd is 28%
- 散户投资者对杭州百拓生物技术有限公司的大量所有权表明,他们在管理和业务战略方面集体拥有更大的发言权
- 55% 的业务由前三名股东持有
- 杭州百拓生物技术有限公司的内部所有权为28%
To get a sense of who is truly in control of Hangzhou Biotest Biotech Co.,Ltd. (SHSE:688767), it is important to understand the ownership structure of the business. We can see that retail investors own the lion's share in the company with 35% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
了解谁真正控制了杭州百拓生物技术有限公司, Ltd.(上海证券交易所代码:688767),了解企业的所有权结构很重要。我们可以看到,散户投资者拥有该公司的大部分股份,所有权为35%。也就是说,如果股票上涨,该集团将受益最大(如果出现低迷,则损失最大)。
Clearly, retail investors benefitted the most after the company's market cap rose by CN¥404m last week.
显然,在上周该公司的市值上涨了4.04亿元人民币之后,散户投资者受益最大。
Let's delve deeper into each type of owner of Hangzhou Biotest BiotechLtd, beginning with the chart below.
让我们从下图开始,深入研究杭州百拓生物技术有限公司的每种类型的所有者。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240501/0-3dae5bc3da487f94b705218d600ea09e-0-a2a775d655baa0062a20fdf9cee7cd0e.png/big)
What Does The Institutional Ownership Tell Us About Hangzhou Biotest BiotechLtd?
关于杭州百拓生物技术有限公司,机构所有权告诉我们什么?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
许多机构根据近似于当地市场的指数来衡量自己的表现。因此,他们通常会更多地关注主要指数中包含的公司。
Less than 5% of Hangzhou Biotest BiotechLtd is held by institutional investors. This suggests that some funds have the company in their sights, but many have not yet bought shares in it. If the company is growing earnings, that may indicate that it is just beginning to catch the attention of these deep-pocketed investors. It is not uncommon to see a big share price rise if multiple institutional investors are trying to buy into a stock at the same time. So check out the historic earnings trajectory, below, but keep in mind it's the future that counts most.
杭州百拓生物技术有限公司不到5%的股份由机构投资者持有。这表明一些基金将目光投向了该公司,但许多基金尚未购买该公司的股票。如果该公司正在增加收益,那可能表明它才刚刚开始引起这些财力雄厚的投资者的注意。如果多个机构投资者试图同时买入股票,股价大幅上涨的情况并不少见。因此,请查看下面的历史收益轨迹,但请记住,最重要的是未来。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240501/0-3dae5bc3da487f94b705218d600ea09e-1-347a7406a937c5048aaa91914dc78cb6.png/big)
We note that hedge funds don't have a meaningful investment in Hangzhou Biotest BiotechLtd. Our data shows that Hangzhou Tuokang Investment Co., Ltd. is the largest shareholder with 23% of shares outstanding. For context, the second largest shareholder holds about 20% of the shares outstanding, followed by an ownership of 11% by the third-largest shareholder. Additionally, the company's CEO Shujiang Wu directly holds 2.1% of the total shares outstanding.
我们注意到,对冲基金没有对杭州百拓生物技术有限公司进行有意义的投资。我们的数据显示,杭州拓康投资有限公司是最大股东,已发行股份的23%。就背景而言,第二大股东持有约20%的已发行股份,其次是第三大股东持有11%的所有权。此外,该公司首席执行官吴树江直接持有已发行股份总额的2.1%。
After doing some more digging, we found that the top 3 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
在进一步挖掘之后,我们发现前三名股东共同控制了公司一半以上的股份,这意味着他们拥有影响公司决策的巨大权力。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.
虽然研究公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向哪个方向吹来也是有意义的。据我们所知,没有分析师对该公司进行报道,因此它可能处于雷达之下。
Insider Ownership Of Hangzhou Biotest BiotechLtd
杭州百拓生物技术有限公司的内部所有权
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
不同国家对内部人员的定义可能略有不同,但董事会成员总是计算在内。公司管理层经营业务,但首席执行官将向董事会负责,即使他或她是董事会成员。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多数人认为内部所有权是积极的,因为这可能表明董事会与其他股东关系良好。但是,在某些情况下,过多的权力集中在该群体中。
Our most recent data indicates that insiders own a reasonable proportion of Hangzhou Biotest Biotech Co.,Ltd.. It has a market capitalization of just CN¥3.1b, and insiders have CN¥862m worth of shares in their own names. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.
我们最新的数据表明,内部人士拥有杭州百拓生物技术有限公司合理比例的股份。,有限公司。它的市值仅为31亿元人民币,内部人士以自己的名义持有价值8.62亿元人民币的股票。这可能表明创始人仍然拥有大量股份。你可以点击这里查看他们是否在买入或卖出。
General Public Ownership
一般公有制
With a 35% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Hangzhou Biotest BiotechLtd. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
杭州百拓生物技术有限公司拥有35%的所有权,主要由个人投资者组成,对杭州百拓生物技术有限公司有一定程度的影响力。这种所有权规模虽然可观,但如果决策与其他大股东不同步,可能不足以改变公司政策。
Private Company Ownership
私人公司所有权
We can see that Private Companies own 35%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
我们可以看到,私人公司拥有已发行股份的35%。仅凭这一事实很难得出任何结论,因此值得研究谁拥有这些私营公司。有时,内部人士或其他关联方通过单独的私人公司对上市公司的股份拥有权益。
Next Steps:
后续步骤:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For example, we've discovered 3 warning signs for Hangzhou Biotest BiotechLtd that you should be aware of before investing here.
我觉得看看究竟谁拥有一家公司非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。例如,我们发现了杭州百拓生物技术有限公司的3个警告信号,在投资这里之前,你应该注意这些信号。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,来看看这份有趣的公司的免费清单吧。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。